LONDON--(BUSINESS WIRE)--Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, notes the publication today of the final phase I data from the first ever ...

Purpose: The pharmacology, efficacy, dosage, adverse events, and economics of omalizumab are discussed. Summary: Omalizumab, a recombinant DNA-derived humanized monoclonal antibody, binds to the Cε3 ...

Whereas natural tolerance rates are generally high for common allergens, such as eggs, milk, and wheat, allergies to other foods often persist beyond childhood. For instance, approximately 72.2% of ...

It is estimated that around 10% of the US population has peanut allergies, a medical emergency that can be treated but not cured. Compared to those without allergies, these individuals are at a ...

The immunoglobulin E (IgE) antibody is a key mediator of allergic responses in food allergies and allergic rhinitis, commonly known as hay fever. In someone with an allergy, the immune system ...

In vitro, omalizumab and human IgE form several immune complexes that vary in size as the 2 components' molar ratios are changed. [29] The largest complex, a stable cyclical hexameric structure ...

Antibody treatment which activates the patient's own immune system against cancer, known as immunotherapy, is increasingly being investigated as an alternative for chemotherapy and radiotherapy. This ...

Maria Curotto de Lafaille’s lab was trying to make human plasma cells in a dish. These weren’t just run-of-the-mill cells, though. The team was vying for something specific: plasma cells that churn ...

TVM Capital Life Science has invested $25 million in Lamab Biologics Inc., which is taking forward a new twist on an old story in tackling allergic conditions. The asset-centric virtual company is ...

Researchers led by the Institut Pasteur, Université Paris, have developed a vaccine that elicits anti-Immunoglobulin E antibodies in humanized mice, protects against Immunoglobulin E-mediated ...